The strong Phase 2 data significantly de-risks ABCL635 and supports best-in-class positioning. Traders should monitor for Phase 3 initiation, additional data at medical conferences later this year, and regulatory interactions. The stock may re-rate upward given the large unmet need and potential to capture share from approved NK3R small molecules.
Price Chart
Executive Summary
AbCellera announced positive top-line Phase 2 results for ABCL635, an NK3R antagonist antibody for moderate-to-severe vasomotor symptoms (hot flashes). The single 600 mg subcutaneous dose met primary endpoints with statistically significant reductions in VMS frequency (83% vs 33% placebo, p<0.001) and severity (58% vs 12% placebo, p<0.001) at week 4, with a favorable safety profile (no SAEs or severe AEs in the treatment group). The data suggest best-in-class potential versus approved small-molecule NK3R antagonists and support advancement to late-stage development.
Key Facts
- Phase 2 trial enrolled 92 postmenopausal women; randomized 1:1 to single 600 mg SC ABCL635 or placebo.
- Mean placebo-adjusted reduction in VMS frequency at week 4: 5.3 events/day (p<0.001); 83% reduction ABCL635 vs 33% placebo.
- Mean placebo-adjusted reduction in VMS severity score at week 4: 1.1 points (p<0.001); 58% reduction ABCL635 vs 12% placebo.
- No serious adverse events or Grade 3+ AEs in the ABCL635 group; headache (28.2%) and fatigue (13.0%) most common AEs.
- 84% of ABCL635 patients rated symptoms as 'Much Better' or 'Moderately Better' on PGI-C vs 27% placebo.
- Significant improvement in sleep disturbance (PROMIS-SD-SF-8b T-score change -5.5 vs placebo, p<0.001).
- Company plans regulatory interactions for late-stage development in VMS due to menopause and oncology treatments.
Financial Impact
Phase 2 success de-risks ABCL635, targeting a $6B+ total addressable market for non-hormonal VMS treatments per management estimates. No financial data in filing.
Risk Factors
- Phase 3 failure or safety issues in larger, longer-duration trials
- Competitive pressure from approved NK3R antagonists (fezolinetant, elinzanetant) and other non-hormonal therapies
- Regulatory delays or additional clinical data requirements
- Cross-trial comparisons are not head-to-head and may not replicate in Phase 3
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001703057-26-000053 |
| Document: abcl635phase2clinicalupd.htm | 0001703057-26-000053 |
| Document: a2026-08x10abcl635phase2.htm | 0001703057-26-000053 |
| Document: 0001703057-26-000053-index-headers.html | 0001703057-26-000053 |
| Document: 0001703057-26-000053-index.html | 0001703057-26-000053 |
| Document: 0001703057-26-000053.txt | 0001703057-26-000053 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 24, 2026 5w ago | Insider Cluster | $10.61 $12.65 | ▲ +19.23% | ▲ +17.91% | $13.74 (+29.50%) |
Aug 18, 2026 6w ago | Insider Cluster | $11.12 $11.67 | ▲ +4.95% | ▲ +6.69% | $13.74 (+23.56%) |
Aug 15, 2026 6w ago | Institutional Cluster | $11.20 $11.41 | ▼ −1.88% | ▼ −3.85% | $13.74 (−22.68%) |
Aug 11, 2026 7w ago | 424B5 | $10.36 $10.46 | ▼ −1.01% | ▼ −2.91% | $13.74 (−32.69%) |
Aug 10, 2026 7w ago | 8-K | $9.34 $11.44 | ▲ +22.48% | ▲ +23.40% | $13.74 (+47.11%) |
Jul 29, 2026 9w ago | 8-K | $5.39 $12.24 | ▲ +127.09% | ▲ +122.07% | $13.74 (+154.92%) |
Jul 6, 2026 12w ago | 3 | $7.69 $5.83 | ▼ −24.19% | ▼ −25.52% | $13.74 (+78.67%) |
Jul 6, 2026 12w ago | 8-K | $7.87 $5.71 | ▼ −27.45% | ▼ −26.88% | $13.74 (+74.59%) |
Jun 5, 2026 17w ago | 8-K | $5.62 $7.87 | ▲ +40.04% | ▲ +38.17% | $13.74 (+144.48%) |
May 11, 2026 20w ago | 8-K | $4.95 $5.09 | ▲ +2.83% | ▲ +4.56% | $13.74 (+177.58%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access